Team & history
Publications & IP

Dybly's team consists of industry veterans who have concentrated on keeping the burn rate low. Investments have been used to further the science, not infrastructure or payroll.

Barbara Staehelin, CEO
(1963, Swiss, American). MSc Biochemistry ETH, MBA INSEAD, Health Economist.
Serial entrepreneur, Executive Committee member Diagnostics division, head of Clinical and Market development, head of Licensing and Alliances at F. Hoffmann-La Roche. Board member at leading Swiss health insurance, Winner of the Veuve Clicquot business woman of the year award.

Herman Kempen, CSO
(1947, Dutch). PhD Biochemistry University of Nijmegen.
Head of research and drug discovery teams in the area of lipids and atherosclerosis for over 20 years, published 100 papers and several patents. Gaubius Institute TNO, Leiden, member of the institute’s Management Team and leader of the Lipid and Atherosclerosis Group. Recruited to head up the Biology Department Metabolic Diseases Research at F. Hoffmann-La Roche in Basel. Broad business development and licensing experience and extensive network in the cardiovascular field (Roche, The Medicines Company, Speedel).

Company history

Dybly was founded in December 2006 by the current management team. Initial funding was granted by EVA, the Basel start-up catalyst. Based on promising results, an angel investor round was closed in 2008. The funds were used to advance a first generation of molecules, testing for activity in ApoA1 upregulation with the intent to shrink atherosclerotic plaques. Scientific results showed that the molecules required further optimization. This phase of research was achieved through a joint venture with a US-based company. This JV was active from 2011 - 2017. During this time, science in this field advanced significantly, enabling us to demonstrate applications outside the originally intended field. In 2018, Dybly secured the rights to the intellectual property generated in this venture and is free to pursue all clinical applications of these exciting molecules.

Our office is located in the house which was the last home of renowned scholar Erasmus of Rotterdam.